Pharmacotherapy for restless legs syndrome

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 8, 2014, Pages 1127-1138

  Ferini Strambi, Luigi ^a   Marelli, Sara ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Augmentation; Dopamine; Dopamine agonists; Opioids; Restless legs syndrome; 2 ligands

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CARBIDOPA PLUS LEVODOPA; CODEINE; DOPAMINE RECEPTOR STIMULATING AGENT; FERRIC CARBOXYMALTOSE; GABAPENTIN; GABAPENTIN ENACARBIL; IRON DEXTRAN; IRON SACCHARATE; LEVODOPA; METHADONE; NALOXONE PLUS OXYCODONE; OXYCODONE; PRAMIPEXOLE; PREGABALIN; ROPINIROLE; ROTIGOTINE; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; CALCIUM CHANNEL BLOCKING AGENT; NARCOTIC ANALGESIC AGENT;

BEDTIME DOSAGE; COMORBIDITY; DEPRESSION; DRUG THERAPY; HUMAN; INSOMNIA; OBESITY; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; REVIEW; SLEEP; SOCIAL INTERACTION; ANIMAL;

ANALGESICS, OPIOID; ANIMALS; CALCIUM CHANNEL BLOCKERS; DOPAMINE AGONISTS; HUMANS; RESTLESS LEGS SYNDROME;

EID: 84900826641     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.908850     Document Type: Review

References (108)

1. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institute of Health. Sleep Med 2003;4:101-19
2. International restless legs syndrome study group. Revised IRLSSG diagnostic criteria for RLS. 2012. Available from: http://irlssg.org/diagnostic- criteria/
3. Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol 2010;6:337-46
4. Montplaisir J, Allen R, Walters A, Ferini-Strambi L. Restless legs syndrome and periodic limb movements during sleep. In: Kryger H, Roth T, Dement WC, editors. "Principles and practice of sleep medicine". 4th edition. Elsevier, Philadelphia, PA; 2005. p. 839-52
5. Michaud M, Paquet J, Lavigne G, et al. Circadian rhythm of restless legs syndrome symptoms: relationship with salivary melatonin, core body temperature and subjective vigilance. Ann Neurol 2004;55:372-80
6. Zucconi M, Ferri R, Allen R, et al. The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med 2006;7:175-83
7. Winkelmann J, Wetter TC, Collado-Seidel V, et al. Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep 2000;23:597-602
8. Whittom S, Dauvilliers Y, Pennestri MH, et al. Age-at-onset in restless legs syndrome: a clinical and polysomnographic study. Sleep Med 2007;9:54-9
9. Hening W, Walters A, Allen RP, et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms and treatment) primary care study. Sleep Med 2004;5:237-46
10. Garcia-Borreguero D, Egatz R, Winkelmann J, Berger K. Epidemiology of restless legs syndrome: the current status. Sleep Med Rev 2006;10:153-67
11. Allen RP, Walters A, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286-92
12. Budhiraja P, Budhiraja R, Goodwin JL, et al. Incidence of restless legs syndrome and its correlates. J Clin Sleep Med 2012;8(2):119-24
13. Szentkiralyi A, Fendrich K, Hoffmann W, et al. Incidence of restless legs syndrome in two population-based cohort studies in Germany. Sleep Med 2011;12(9):815-20
14. Kagimura T, Nomura T, Kusumi M, et al. Prospective survey on the natural course of restless legs syndrome over two years in a closed cohort. Sleep Med 2011;12(9):821-6
15. Allen RP, Barker PB, Wehrl F, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001;56:263-5
16. Earley CJ, Barker P, Horska A, Allen RP. MRI-determined regional brain iron concentrations in early-and late-onset restless legs syndrome. Sleep Med 2006;7:458-61
17. Connor JR, Wang XS, Patton SM, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 2004;62:1563-7
18. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 2004;5(4):385-91
19. Connor JR, Wang XS, Allen RP, et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain 2009;132:2403-12
20. Clemens S, Hochman S. Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J Neurosci 2004;24:11337-45
21. Earley CJ, Allen RP, Connor JR, et al. The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal. Sleep Med 2009;10:1155-7
22. Rios Romenets S, Dauvilliers Y, Cochen de Cock V, et al. Restless legs syndrome outside the blood-brain barrier-exacerbation by domperidone in Parkinson's disease. Parkinsonism Relat Disord 2013;19:92-4
23. Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med 2010;11:848-56
24. Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004;27:907-14
25. Walters AS, Ondo WG, Zhu W, Le W. Does the endogenous opiate system play a role in the restless legs syndrome? A pilot post-mortem study. J Neurol Sci 2009;279:62-5
26. Allen RP, Barker PB, Horská A, Earley CJ. Thalamic glutamate/glutamine in restless legs syndrome: increased and related to disturbed sleep. Neurology 2013;80(22):2028-34
27. Oertel WH, Trenkwalder C, Zucconi M, et al. State of the art in restless legs syndrome: practice recommendations for treating restless legs syndrome. Mov Disord 2007;22(Suppl 18):S466-75
28. Garcia-Borreguero D, Stillman P, Benes H, et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol 2011;11:28
29. Walters AS, LeBrocq C, Dhar A, et al. The International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs. Sleep Med 2003;4:121-32
30. Ferri R, Fulda S, Manconi M, et al. Night-to-night variability of periodic leg movements during sleep in restless legs syndrome and periodic limb movement disorder: comparison between the periodicity index and the PLMS index. Sleep Med 2013;14(3):293-6
31. Godau J, Spinnler N, Wevers AK, et al. Poor effect of guideline based treatment of restless legs syndrome in clinical practice. J Neurol Neurosurg Psychiatry 2010;81:1390-5
32. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 1982;39:739
33. Trenkwalder C, Stiasny K, Pollmacher T, et al. L-Dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, cross-over trial. Sleep 1995;18:681-8
34. Stiasny-Kolster K, Kohnen R, Moller JC, Oertel W. Validation of "L-dopa test" for diagnosis of restless legs syndrome. Mov Disord 2006;21:1333-9
35. von Scheele C, Kempi V. Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up. Arch Neurol 1990;47:1223-4
36. Early CJ, Allen RP. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996;19:801-10
37. Garcia-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007;8:520-30
38. Vignatelli L, Billiard M, Clarenbach P, et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006;13:1049-65
39. Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 1999;52:285-90
40. Trenkwalder C, Collado-Seidel V, Kazenwadel J, et al. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome? Mov Disord 2003;18:1184-9
41. Garcia-Borreguero D, Kohnen R, Hogl B, et al. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levo-dopa in RLS. Sleep Med 2007;8:455-63
42. de Biase S, Merlino G, Lorenzut S, et al. ADMET considerations for restless leg syndrome drug treatments. Expert Opin Drug Metab Toxicol 2012;8:1247-61
43. Manconi M, Ferri R, Zucconi M, et al. Pramipexole versus ropinirole: polysomnographic acute effects in restless legs syndrome. Mov Disord 2011;26:892-5
44. Walters AS, Hening WA, Kavey N, et al. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 1988;24:455-8
45. Wetter TC, Stiasny K, Winkelmann J, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999;52:944-50
46. Stiasny K, Wetter TC, Winkelmann J, et al. Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology 2001;56:1399-402
47. Stiasny K, Robbecke J, Schuler P, et al. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline-an open clinical trial. Sleep 2000;23:349-54
48. Stiasny-Kolster K, Benes H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 2004;63:2272-9
49. Zucconi M, Oldani A, Castronovo V, Ferini Strambi L. Cabergoline is an effective single-drug treatment for restless legs syndrome: clinical and actigraphic evaluation. Sleep 2003;26:815-18
50. Trenkwalder C, Benes H, Grote L, et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multicenter, randomized, active controlled trial. Mov Disord 2007;22:646-703
51. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-9
52. Zanetti R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46
53. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and he isk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38
54. Montplaisir J, Nicolas A, Denesle R, et al. Pramipexole alleviates sensory and motor symptoms of restless legs syndrome. Neurology 1998;51:311-12
55. Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole il RLS: a six-week, multicenter, randomized, double-blind study. Mov Disord 2007;22:213-19
56. Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep 2003;26:819-21
57. Winkelman JW, Johnston L. Augmentation and tolerance with longterm pramipexole treatment of restless legs syndrome. Sleep Med 2004;5:9-14
58. Montplaisir J, Fantini ML, Desautels A, et al. Long-term treatment with pramipexole in restless legs syndrome. Eur J Neurol 2006;13:1306-11
59. Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med 2008;9(8):874-81
60. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Therapy with ropinirole, efficacy and tolerability in RLS-1 Study Group. Ropinirole in the treatment of RLS: results from the TREAT RLS-1 study, a 12 week, randomized, placebo controlled study in 10 european countries. J Neurol Neurosurg Psychiatry 2004;75:92-7
61. Montplaisir J, Karrasch J, Haan J, et al. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord 2006;21:1627-35
62. Garcia-Borreguero D, Grunstein R, Sridhar G, et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med 2007;8:742-52
63. García-Borreguero D, Högl B, Ferini-Strambi L, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord 2012;27(2):277-83
64. Quilici S, Abrams KR, Nicolas A, et al. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med 2008;9:715-26
65. Moller C, Korner Y, Cassel W, et al. Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome. Sleep Med 2006;7:333-9
66. Wilt TJ, MacDonald R, Ouellette J, et al. Pharmacologic therapy for primary restless legs syndrome: a systematic review and meta-analysis. JAMA Intern Med 2013;173:496-505
67. Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604
68. Oertel W, Trenkwalder C, Benes H, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 2011;10:710-20
69. Oertel WH, Benes H, Garcia-Borreguero D, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2007;9:228-39
70. Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol 2012;19(11):1385-96
71. Garcia-Barreguero D, Larrosa de la Liave Y, Verger K, et al. Treatment of restless legs syndrome with gabapentin. Neurology 2002;59:1573-9
72. Winkelman JW, Bogan RK, Schmidt MH, et al. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord 2011;26:2065-72
73. Lee DO, Ziman RB, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med 2011;7:282-92
74. Kushida CA, Becker PM, Ellenbogen AL, et al. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009;72:439-46
75. Ellenbogen AL, Thein SG, Winslow DH, et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clin Neuropharmacol 2011;34:8-16
76. Saletu M, Anderer P, Saletu-Zyhlarz GM, et al. Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. J Neural Transm 2010;117:463-73
77. Allen R, Chen C, Soaita A, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med 2010;11:512-19
78. Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med 2013;14:675-84
79. Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 2014;370(7):621-31
80. Walters AS, Wagner ML, Hening WA, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993;16:327-32
81. Walters AS, Winkelmann J, Trenkwalder C, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001;6:1105-9
82. Ondo WG. Methadone for refractory restless legs syndrome. Mov Disord 2005;20:345-8
83. Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med 2011;12:440-4
84. Trenkwalder C, Benes H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 2013;12:1141-50
85. Silber MH, Becker PM, Earley C, et al. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc 2013;88(9):977-86
86. Manconi M, Ferri R, Zucconi M, et al. Dissociation of periodic leg movements from arousals in restless legs syndrome. Ann Neurol 2012;71(6):834-44
87. Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidencebased review and implications for clinical practice. Mov Disord 2008;23:2267-302
88. Sun ER, Chen CA, Ho G, et al. Iron and the restless legs syndrome. Sleep 1998;21:371-7
89. Cho YW, Allen RP, Earley CJ. Lower molecular weight intravenous iron dextran for restless legs syndrome. Sleep Med 2013;14:274-7
90. Earley CJ. The importance of oral iron therapy in restless legs syndrome. Sleep Med 2009;10:945-6
91. Trotti LM, Bhadriraju S, Becker LA. Iron for restless legs syndrome. Cochrane Database Syst Rev 2012;5:CD007834
92. Ondo WG. Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Med 2010;11:494-6
93. Allen RP, Adler CH, Du W, et al. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med 2011;12:906-13
94. Earley CJ, Horska A, Mohamed MA, et al. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med 2009;10:206-11
95. Morcos Z. Restless legs syndrome, iron deficiency and colon cancer. J Clin Sleep Med 2005;1:433
96. Giannaki C, Hadjigeorgiou MG, Karatzaferi C, et al. Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review. Kidney Int 2013;online publication 9 October 2013, doi:10.1038/ki.2013.394
97. Stautner A, Stiasny K, Collado-Seidel V, et al. Comparison of idiopathic and uremic restless legs syndrome: results of a database of 134 patients. Mov Disord 1996;11:98
98. Kutner NG, Zhang R, Szczech LA, et al. Restless legs syndrome reported by incident haemodialysis patients: is treatment time of day relevant? Nephrology (Carlton) 2012;17:783-4
99. Manconi M, Govoni V, De Vito A, et al. Restless legs sindrome and pregnancy. Neurology 2004;63:1065-9
100. Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002;53:547-54
101. Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2008;43:70-5
102. Hornyak M, Voderholzer U, Riemann D. Treatment of depression in patients with restless legs syndrome: what is evidence-based? Sleep Med 2006;7:301-2
103. Chokroverty S. Long-term management issues in restless legs syndrome. Mov Disord 2011;26:1378-85
104. Manconi M, Ferri R, Zucconi M, et al. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. Sleep Med 2007;8(5):491-7
105. Dresler M, Spoormaker VI, Beitinger P, et al. Neuroscience-driven discovery and development of sleep therapeutics. Pharmacol Ther 2014;141(3):300-34
106. Ferini-Strambi L, Walters AS, Sica D. The relationship among restless legs syndrome (Willis-Ekbom Disease), hypertension, cardiovascular disease, and cerebrovascular disease. J Neurol 2013. [Epub ahead of print]
107. Cosentino FI, Aricò D, Lanuzza B, et al. Absence of cardiovascular disease risk factors in restless legs syndrome. Acta Neurol Scand 2012;125(5):319-25
108. Winter AC, Schürks M, Glynn RJ, et al. Vascular risk factors, cardiovascular disease, and restless legs syndrome in women. Am J Med 2013;126(3):220-7